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ABSTRACT Out of the five members of the Ebolavirus family, four cause life-
threatening disease, whereas the fifth, Reston virus (RESTV), is nonpathogenic in hu-
mans. The reasons for this discrepancy remain unclear. In this review, we analyze the
currently available information to provide a state-of-the-art summary of the factors
that determine the human pathogenicity of Ebolaviruses. RESTV causes sporadic in-
fections in cynomolgus monkeys and is found in domestic pigs throughout the Phil-
ippines and China. Phylogenetic analyses revealed that RESTV is most closely related
to the Sudan virus, which causes a high mortality rate in humans. Amino acid se-
quence differences between RESTV and the other Ebolaviruses are found in all nine
Ebolavirus proteins, though no one residue appears sufficient to confer pathogenic-
ity. Changes in the glycoprotein contribute to differences in Ebolavirus pathogenicity
but are not sufficient to confer pathogenicity on their own. Similarly, differences in
VP24 and VP35 affect viral immune evasion and are associated with changes in hu-
man pathogenicity. A recent in silico analysis systematically determined the func-
tional consequences of sequence variations between RESTV and human-pathogenic
Ebolaviruses. Multiple positions in VP24 were differently conserved between RESTV
and the other Ebolaviruses and may alter human pathogenicity. In conclusion, the
factors that determine the pathogenicity of Ebolaviruses in humans remain insuffi-
ciently understood. An improved understanding of these pathogenicity-determining
factors is of crucial importance for disease prevention and for the early detection of
emergent and potentially human-pathogenic RESTVs.
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The recent Ebola virus (EBOV) outbreak in West Africa changed our perception of theglobal threat posed by the Ebolaviruses. The outbreak was of unprecedented size,
resulting in 28,657 confirmed cases and 11,325 deaths (as of 5 August 2016 [http://
www.who.int]), with several reported deaths on other continents (1). Previous Ebola-
virus outbreaks ranged from a very few infected individuals to a few hundred cases (2).
During this outbreak, evidence has emerged that EBOVs were able to persist and
remain infective in immune-privileged sites in the body (including the eye, semen,
vaginal fluid, and breast milk) for over 6 months after disease resolution and clearance
of the virus from the bloodstream, significantly complicating disease containment and
control (3, 4). The combination of these factors (outbreak size and virus persistence)
raises significant concern for the danger posed by future outbreaks. Advancing our
understanding of Ebolaviruses is extremely important in order to ensure adequate
surveillance and outbreak containment; however, much remains unknown about the
mechanisms by which these viruses cause disease.
Ebolaviruses are filoviruses (filamentous viruses) with a single-stranded negative-
sense RNA genome. The Ebolavirus family consists of five species, Zaire ebolavirus (type
virus, EBOV), Sudan ebolavirus (type virus, Sudan virus [SUDV]), Tai Forest ebolavirus
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(type virus, Tai Forest virus [TAFV]), and Bundibugyo ebolavirus (type virus, Bundibugyo
virus [BDBV]), and Reston ebolavirus (type virus, Reston virus, RESTV). EBOV, SUDV, TAFV,
and BDBV cause severe hemorrhagic disease in humans, with mortality rates ranging
from 50 to 90% (5, 6). RESTV is mildly virulent in pigs, avirulent in humans, but lethal
in nonhuman primates (NHPs), although African green monkeys (Chlorocebus aethiops)
are resistant to RESTV infection and baboons (Papio hamadryas) are resistant to both
RESTV and EBOV infections (7–11). Coinfection with other pathogenic viruses may also
have a role in the modulationof RESTV disease severity, as simian hemorrhagic fever
virus has been found in fatal cases of RESTV infections in NHPs, though the contribution
of each pathogen to the overall disease remains unknown (12).
The Ebolavirus genome is approximately 19 kb in length and encodes nine proteins,
nucleoprotein (NP), glycoprotein (GP), soluble GP (sGP), small soluble GP (ssGP), RNA-
dependent RNA polymerase (L), and structural proteins VP24, VP30, VP35, and VP40, many
of which are associated with viral pathogenicity (Table 1) (13–15). Each of the viral proteins
shows a high degree of sequence conservation among the different Ebolavirus species, and
no single protein appears to be sufficient to confer a pathogenic phenotype on RESTV. As
a result, the risks of RESTV mutating into a human-pathogenic strain remain unknown and
therefore, the virus remains classified as a biosafety level 4 pathogen.
While the four human-pathogenic Ebolavirus species are all found in Africa, RESTV is
known to be endemic to the Philippines and China. This makes RESTV the only
Ebolavirus known to exist outside Africa to date. RESTV was discovered by electron
microscopic examination of infected cells during the 1989 epizootic outbreak in
cynomolgus monkeys that had been imported from the Philippines into the United
States and housed at a research facility in Reston, VA (16). The monkeys displayed the
hallmark symptoms of Ebolavirus disease, including subcutaneous hemorrhaging,
bloody diarrhea, and sudden onset of anorexia (12). In contrast, four handlers in the
United States who became infected with RESTV did not show any signs or symptoms
of illness, nor did the seropositive handlers at the Laguna export facility in the
Philippines (17). Since then, several known minor outbreaks of RESTV have occurred in
monkeys (Fig. 1): a subsequent outbreak in 1990 in Reston, VA, in which four handlers
developed antibodies to RESTV; a 1992 outbreak in Sienna, Italy, in monkeys imported
from the same facility in the Philippines that caused the 1989 outbreak; a 1996
outbreak in Alice, TX, at the Texas Primate Center; and two outbreaks in 1996 and 2015
in the Philippines (12, 16).
In 2008, RESTV was found in farmed pigs in Manila, the Philippines (8) (Table 2). Six
handling personnel were found to be seropositive for RESTV, suggesting RESTV trans-
mission from pigs to humans. Interestingly, RESTV was only found in sick pigs that were
TABLE Protein components of Ebolavirusa
Protein Function
% of RESTV residues
identified as SDPs
NP Protects and packages the viral genome by encapsidation 3.87
GP Class I viral fusion protein, responsible for binding and entry into host cells, activated by proteolysis,
creating GP1 and GP2; GP1,2 has extensive roles in modulation of the immune response and alteration
of the expression of cell surface adhesion molecules; cleavage of GP1,2 from the plasma membrane
creates a soluble variant
4.3
sGP Possible roles in immune evasion and alteration of endothelial permeability 2.43
ssGP Unknown Not determined
VP24 Secondary matrix protein, minor component of virions; key player in pathogenicity, inhibits components
of immune response
3.59
VP30 Viral nucleocapsid component; key role in transcription depending on its state of phosphorylation 5.86
VP35 Polymerase cofactor in transcription and replication; prevents antiviral response in cells by blocking IRF-3
and protein kinase EIF2AK2/PKR
5.57
VP40 Regulates viral transcription, morphogenesis, packaging, and budding 2.72
Polymerase Replicates the viral genome 2.95
aThe percentage of SDP sites in RESTV, compared to EBOV, may offer clues to the lack of RESTV pathogenicity in humans, though higher levels of SDPs do not
necessarily indicate a change in protein function or activity. Furthermore, the percentage of difference is likely to fluctuate regularly because of viral mutation and
evolution (49, 58, 65–69).
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also infected with porcine reproductive and respiratory syndrome virus (PRRSV), al-
though histological analysis did not reveal colocalization of the two viruses at any body
site. Whether RESTV contributed to the manifested symptoms remains to be deter-
mined (9). The viral genome sequences isolated from pigs in 2008 exhibited a 2.5%
mean difference in nucleotide sequence identity from the 1989 Reston monkey isolate.
Three RESTV samples recently taken from infected pigs at different geographical
locations in the Philippines (Panganisan and Bulacan) showed even greater divergence
from each other, with a 3.93% mean difference in nucleotide sequence identity (8). It
was suggested that the reason for this genetic diversity could be that both monkeys
and pigs were infected from different unidentified reservoirs (8). In 2012, RESTV was
again detected in pigs with PRRSV, this time in China, with 96.1 to 98.9% sequence
similarity to previous pig and monkey isolates from the Philippines (18).
Despite the fact that the first known RESTV outbreak occurred almost 30 years ago,
there is still relatively little known about this virus. This includes the natural reservoirs
of RESTV, the route of transmission from this reservoir to pigs and monkeys, and the
reasons underlying its lack of pathogenicity in humans. Because of its similarity to the
other four Ebolaviruses, there is a concern that RESTV could mutate to become
pathogenic in humans and that this Ebolavirus could then spread easily around the
FIG 1 Detection of RESTV. The maps shown indicate the locations of RESTV detection, either viral
RNA or seropositive evidence, that suggest that RESTV is more widely distributed than previously
thought (7, 18, 19, 25). The distribution of RESTV appears to be in close proximity to the equator,
similar to that of other Ebolaviruses, although RESTV has never been detected in Africa.
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world through imported livestock or other animal hosts. In this review, we will discuss
potential reservoirs for RESTV, its genetic relationship to other Ebolaviruses, and the
molecular basis for its lack of pathogenicity in humans. We will also speculate on the
potential risk of RESTV to human health and how this can be addressed.
RESTV HOSTS AND RESERVOIRS
Circulation of RESTV in reservoir species and other hosts may increase the probability
that human-pathogenic RESTV variants will emerge, in particular if selective pressures
exerted by different hosts cause viral mutation or if the host range results in more
frequent contact with humans. To date, it is known that RESTV can infect humans,
NHPs, and pigs. However, it is often suggested that there are reservoirs of this virus that
have not yet been identified (8, 19). Bats are the most commonly implicated reservoirs
of filoviruses (20–22). In 2008 and 2009, Rousettus amplexicaudatus fruit bats possessing
RESTV-specific IgG antibodies were captured in the Philippine forests of Diliman and
Cuezon, located within 60 km of the Bulacan farm where RESTV-infected monkeys were
identified in 2008 (23). R. amplexicaudatus bats are genetically similar to R. aegyptiacus
bats, which are thought to be the reservoir of Ebolaviruses in Africa (24). In addition,
RESTV, as well as EBOV, antibodies have been found in Bangladesh and China in the
related bat species R. leschenaultia, suggesting that the Ebolaviruses may circulate in a
wide geographical area (19, 25). While live virus has not been detected in these bats,
it is possible that the bats could rapidly clear the viral infections or restrict viral
replication to levels that are below the limit of detection.
RESTV was also detected in domestic pigs in Shanghai, China, that were coinfected
with PRRSV. The RESTV sequence was found to be 96.1 to 98.9% identical to that of
strains previously found in domestic pigs and monkeys in the Philippines (18). Exper-
imental infections with RESTV, in the absence of PRRSV, have also been performed to
examine the disease course in pigs. Interestingly, infected pigs were found to have high
viral loads in the lungs and were able to shed the virus through the nasopharynx,
though the pigs showed no disease symptoms (9). This further demonstrates that pigs
are a hosts of RESTV and suggests that, at least in pigs, RESTV may be able to spread
through aerosol transmission. Thus, continued RESTV spread to humans through
contact with domestic animals may increase the likelihood of RESTV adaption and the
possible emergence of a human-pathogenic, aerosol-transmittable RESTV.
RESTV GENOME EVOLUTION
RESTV is thought to have originated in Africa and to have diverged from SUDV about
1,400 to 1,600 years ago before it migrated toward Asia (Fig. 2) (6, 26, 27). The





Philippines 1989–1990 Cynomolgus monkey 3
United States (VA, PA) 1989–1990 Cynomolgus monkey 0
United States (TX) 1989–1990 Cynomolgus monkey 4
Italy 1992–1993 Cynomolgus monkey 0
United States (TX) 1996 Cynomolgus monkey 0
Philippines 1996 Cynomolgus monkey 1
Philippines 2008 Pig 6
China 2011 Pig 0
Philippines 2015 Cynomolgus monkey 0
Locations with seropositive
evidence only
Philippines 2008–2009 Fruit bat
China 2006–2009 Fruit bat
Bangladesh 2010–2011 Fruit bat
aThe 1989 outbreak was characterized by high mortality rates in cynomolgus monkeys, whereas infected
pigs were found to be coinfected with PRRSV. No human handlers were reported to show any symptoms of
disease (7, 8, 17, 19, 70, 71).
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hypothesis that filoviruses have spread beyond the African continent was recently
reinforced by the discovery of a new filovirus in bats in the Lloviu caves of Spain, as well
as the presence of RESTV in bats, pigs, and NHPs in Asia (18, 22, 25).
A recent phylogenetic study analyzed seven RESTV genomes, including four that were
obtained from infected pigs (27). While the virus showed a genetic change of 0.079% in
1 year on the same farm, there was a divergence of up to 4.5% on a different farm (27). This
study also showed that RESTV evolves at a rate of 8.21  104 nucleotide substitutions/
site/year, similar to that of EBOV and much higher than the rate of nucleotide substitutions
of SUDV, which could make the virus more susceptible to adaptation to humans.
The overall selection pressures between EBOV and RESTV show that amino acids on
the main viral antigenic determinant, GP, were under increased selective pressure.
EBOV selection pressure was found to be 0.299, whereas RESTV showed 0.329, whereby
a ratio of 1 indicates increased selection and 1 indicates decreased selection (28).
The EBOV GP showed selective pressure at mucin domain residues 377 and 443,
whereas RESTV GP was only under selective pressure at one glycosylated residue in the
GP1 glycan cap, N229, though this residue was under stronger selection that any in
EBOV GP (29). These changes in GP may result in a different host tropism or may affect
immune evasion, which may be a cause for concern about RESTV, though this has not
been experimentally demonstrated.
DIFFERENCES THAT MAY CONTRIBUTE TO PATHOGENICITY
A number of studies have compared human-pathogenic Ebolaviruses to RESTV in order
to identify the underlying reasons for the observed differences in human pathogenicity
FIG 2 Phylogenetic analysis of the Filoviridae family. Shown are the results of a Bayesian coalescent analysis of viruses in the Filoviridae family showing
that RESTV is most closely related to SUDV (27).
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(30–32). One of the proteins implicated in pathogenesis, VP24, acts by antagonizing the
host innate immune response. VP24 binds to karyopherin 1 (KPNA1), KPNA5, and
KPNA6, inhibiting the nuclear import of phosphorylated (active) STAT1 and restricting
the expression of interferon-stimulated genes (ISGs) (33). VP24 was also found to
reduce the binding of heterogeneous nuclear ribonuclear protein complex C1/C2
(hnRNP C1/C2) to KPNA1, further restricting phosphorylated-STAT1 nuclear import, as
well as relocating hnRNP C1/C2 from the nucleus into the cytoplasm (34). In viruses
such as poliovirus and human papillomavirus, this relocation facilitates viral RNA
replication and the translation of viral proteins (34–36). In addition to blocking the
STAT1 pathway, VP24 may also directly bind to STAT1 to prevent its nuclear import (37).
EBOV VP24 may be more effective at suppressing the host interferon response than
RESTV VP24, as EBOV-infected cells express lower levels of many ISGs than do RESTV-
infected cells (38).
Several VP24 amino acid differences between EBOV and RESTV may affect the virus’s
ability to inhibit STAT1 signaling, thus affecting pathogenicity (39). These variant
residues appear to cluster at key sites involved in VP24 binding to KPNAs, such as the
VP24 142-to-146 loop. In this region, RESTV displays conserved amino acid changes
(M136L, Q139R, R140S) compared to other Ebolavirus species (30). Changing the RESTV
S140 residue to R140 modifies the hydrophobic moment of the protein and appears to
be sufficient to enable KPNA binding (32). These findings suggest that specific changes
in RESTV VP24 may affect interactions with KPNAs, resulting in a reduced ability to
inhibit interferon signaling. In 6- to 8-week-old STAT1 knockout BALB/c mice, both
EBOV and RESTV infections resulted in disease manifestation, causing lethargy, weight
loss, and decreased survival rates after 6 days postinfection. However, wild-type BALB/c
mice (6 to 8 weeks old) showed no manifestation of disease upon infection with either
EBOV or RESTV (40, 41). EBOV was found to be lethal only in newborn mice or following
several rounds of adaptation; however, comparable experiments have not been per-
formed with RESTV and thus the ability of RESTV to adapt and cause disease in mice
remains unknown (40, 41). In contrast to the STAT1/ infections, RESTV infection of
alpha/beta interferon receptor (IFNAR) knockout mice resulted in only transient weight
loss, whereas EBOV infection was uniformly lethal (42). Interestingly, following symp-
tom resolution, RESTV-infected IFNAR/ mice showed protection against a subse-
quent challenge with mouse-adapted EBOV (43). These results demonstrate the com-
plexity of investigating Ebolavirus infections and RESTV pathogenicity in mice.
Bioinformatic investigation determined amino acid residues that are differently
conserved (specificity-determining positions [SDPs]) between RESTV and the four
human-pathogenic Ebolavirus species (44, 45). Several of these SDPs were located on
protein surfaces, suggesting their possible involvement in molecular interactions (46).
While the VP24 sequence identity between EBOV and RESTV is 80%, only 9 of 251
residues were identified as SDPs, possibly contributing to RESTV’s lack of pathogenicity
in humans (15). Of the nine SDPs found in VP24, three (T131S, M136L, and Q139R) are
located at the KPNA5 binding site. This supports the hypothesis that RESTV VP24 may
be less effective at karyopherin binding and suppressing the interferon response. In
addition, another SDP in RESTV VP24 results in the loss of hydrogen bonding between
T226 and D48, potentially impacting protein stability and function (46). However, the
SDPs were not restricted to VP24 and many SDPs were found in other protein interfaces
that may affect interactions and stability (Table 1).
VP35 is an interferon antagonist that inhibits the activation of interferon regulatory
factor 3 (IRF3) following the sensing of viral RNA by the pattern recognition receptor
RIG-I. RESTV VP35 has 65% sequence identity with EBOV VP35 and shows 19 SDPs
(46–49). Although, it was found that both RESTV and EBOV VP35 molecules were able
to inhibit IRF-3 activation, blocking the IRF3-dependent transcription of ISGs 54 and 56.
In addition, neither RESTV nor EBOV VP35 could block signaling from the IFNAR (50).
This implies that not all SDPs have an effect on pathogenicity; therefore, the conse-
quences of these differences are not clear.
In addition to VP24, differences in the GP may also affect viral pathogenesis (51, 52).
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EBOV GP contains a mucin-like domain that increases blood vesicle permeability by
downregulating the expression of integrin 1 and other cell adhesion molecules
(53–55). RESTV GP has several conserved SDPs (R325G, H354L, Q403P, S418E, T448P)
and was found to have a significantly weaker influence in downregulating integrin 1
expression, compared to EBOV GP (46, 55). When it was examined in vivo, it was seen
that the presence of the RESTV GP attenuated EBOV pathogenicity, whereas the reverse
genetic conversion of RESTV GP to EBOV GP was not sufficient to confer a pathogenic
phenotype on RESTV, indicating that other proteins are involved in the regulation of
Ebolavirus pathogenicity (38, 42, 55).
The functions of the two soluble and secreted Ebolavirus proteins sGP and ssGP
remain the most elusive, with the structure of EBOV sGP only recently being solved (56).
sGP shares 295 N-terminal residues with GP; thus, sGP is thought to contribute to
evasion of the humoral system by absorbing GP antibodies (57, 58). In addition, sGP
seems to play an anti-inflammatory role by promoting recovery of the endothelial
barrier during Ebolavirus infection (59). RESTV appears to secrete more sGP than EBOV,
suggesting that the anti-inflammatory role of sGP has a more significant role in
pathogenicity, considering its role in restoration of the endothelial barrier (59). At
37 kDa, RESTV ssGP is significantly larger than that of the other Ebolaviruses (33 kDa).
However, the potential involvement of ssGP in pathogenicity remains unclear and thus
the effect of the RESTV ssGP extension is unknown (60).
It may also be that lack of RESTV virulence in humans is due to a delay in viral
transcription and genome replication, as RESTV was found to have slower growth
kinetics, suggesting a growth impairment that was not observed with EBOV (61). The
organization of the RESTV genome differs from that of the other Ebolaviruses. Ebola-
viruses contain gene overlaps between GP and VP30. In contrast, these two genes are
separated by an intergenic region in RESTV (26). This change in genomic organization
may affect the transcription of GP and VP30 or alter the efficiency of genome replica-
tion. Though the relationship between EBOV gene overlap and genomic replication has
not been tested, it is possible that the reduced efficiency of RESTV replication, com-
bined with functional protein differences, could enable RESTV to infect humans without
causing any detectable pathogenicity.
CONCLUSIONS
RESTV is unique among the Ebolaviruses in that it does not cause disease in humans.
However, RESTV is infectious in several animal species that exist in close contact with
humans, and humans can be asymptomatically infected with the virus, raising the
question of whether humans can be carriers of Ebolaviruses and suggesting that further
adaptation of RESTV could cause a significant risk to human health.
An observed significant factor in the outbreak in West Africa was that infected bush
meat provided a route of transmission of virus to humans (62). Humans and R. le-
schenaultia bats in Bangladesh share a food source, date palm sap, which may be a
potential route of viral transmission to humans. In addition, the ability of pigs to
become hosts of RESTV means that the virus can be established in the human food
chain, which is a cause for concern, as prolonged human contact may play a role in
virus adaptation to humans.
Furthermore, it may be the case that single amino acid substitutions in SDP sites can
affect pathogenicity. This is concerning, as many RESTV proteins had only a few SDPs
that differed from those of EBOV, suggesting that a minimal number of mutations may
be required to restore RESTV pathogenicity in humans. Thus, the investigation of the
effects of individual SDPs is of great importance for understanding EBOV pathogenicity.
While the likelihood that RESTV will become pathogenic in humans is not clear,
given that it can establish itself in the human food chain in densely populated areas,
the potential risk that the virus poses to human health worldwide is significant. This risk
is even greater when considering that because RESTV is nonpathogenic in humans, the
only people who have been screened for RESTV infection have worked at monkey and
pig farms undergoing RESTV outbreaks; thus, the actual prevalence of RESTV in human
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and animal populations may be significantly greater than anticipated. However, in
response to the recent outbreak of EBOV in West Africa, research into Ebolavirus
therapeutics has shown promising advances, in particular, vaccines and an antibody for
pan-Ebolavirus therapy that is able to protect mice from lethal EBOV infections (63, 64)
and may be able to prevent and mitigate future outbreaks of any Ebolavirus species,
including RESTV.
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